Current trials: Follicular Lymphoma52

The following clinical trials are currently offered in Germany in this group. More about Follicular Lymphoma

52 matching trials

CHARLYActive, not recruiting

Cyclophosphamide to Reduce Complications Following Haploidentical Stem Cell Transplantation

If non-Hodgkin lymphoma (NHL) cannot be controlled with standard therapy (refractory), a stem cell transplant from a compatible donor may be recommended. In a so-called haploidentical stem cell transplant, the immunological similarity between the donor and the recipient is lower, and rejection reactions may occur as a complication of the transplant. This risk could potentially be reduced by administering a high dose of the drug cyclophosphamide. The aim of the study is to investigate whether high-dose cyclophosphamide administered after a haploidentical stem cell transplant can prolong disease-free survival and reduce the risk of rejection reactions. Women and men aged 18–65 with relapsed or refractory NHL who are receiving a haploidentical allogeneic stem cell transplant are eligible to participate in this study.

18–65 years · Relapsed / refractory · Phase II

INFORM RegistryRecruiting

INFORM Registry Study on Individualized Treatment for Patients with Recurrent Malignant Disease, with a Special Focus on Children and Adolescents

Many types of cancer can now be cured using modern treatment options. Nevertheless, relapses and progressive cancer remain a major challenge. The goal of the INFORM-REGISTER study is to use molecular genetic testing methods to gather information about tumor characteristics that can be used by treating physicians to inform future treatment decisions. Patients aged 0 to 40 with previously treated, treatment-resistant, or progressive cancer who no longer have any established curative treatment options available are eligible to participate in the study.

0–40 years · Relapsed / refractory · Phase IV

GOAL IIActive, not recruiting

GOAL II

The GOAL-II trial is investigating the efficacy of adding a new antibody to existing standard therapy in patients with relapsed aggressive lymphoma.

18–64 years · Relapsed / refractory · Phase II

KPS-R01Recruiting

A registry study on genetically determined cancer risk (cancer predisposition syndromes, CPS) to improve early detection and treatment (CPS-R01 Study)

People with cancer predisposition syndrome (KPS) have an increased lifetime risk of developing certain types of cancer. Consequently, early cancer detection is of great importance in the context of this condition, as it allows tumors to be identified at an early stage and treated as effectively as possible. The goal of the KPS-R01 study is the systematic collection of patient data in a registry. Women and men of any age with a confirmed cancer predisposition syndrome or a strong suspicion of KPS are eligible to participate.

0 years and older · First line · Phase IV

CelestimoActive, not recruiting

A study to evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide, compared with rituximab in combination with lenalidomide, in patients with follicular lymphoma

Follicular lymphoma is a form of lymph node cancer. Treatment depends on the symptoms and the stage of the disease; it may involve radiation therapy, chemotherapy, or specific medications such as antibodies. In most cases, treatment is successful, but there are patients in whom the treatment does not work (refractory) or who experience a relapse. The goal of the CELESTIMO study is to compare the efficacy and safety of the antibody mosunetuzumab in combination with lenalidomide to the established therapy of rituximab and lenalidomide in patients with refractory or relapsed follicular lymphoma. Patients with follicular lymphoma who have already received prior treatment are eligible to participate. The lymphoma must be histologically confirmed and express the CD20 surface protein (CD20+).

18 years and older · Relapsed / refractory · Phase III

ARIADNERecruiting

An observational study of the already approved drug zanubrutinib in the treatment of various blood cancers, to gather more data on the tolerability and safety of the therapy

Zanubrutinib is an already approved drug that can be used to treat patients with Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), or follicular lymphoma (FL). Since some of these conditions are very rare, there is not yet sufficient information on the use of this medication in clinical practice. The ARIADNE study is investigating how the treatment affects patients’ quality of life, including how often it requires inpatient care. Patients who are at least 18 years old and have one of the conditions listed above are eligible to participate in the study.

18 years and older · First line · Phase IV

MK-4280-003Active, not recruiting

Evaluation of the Safety and Efficacy of Combination Therapy with Favezelimab and Pembrolizumab and the Respective Monotherapies in Hodgkin's and Non-Hodgkin's Lymphomas

Lymphomas are a group of blood cancers that affect the lymphatic system. They are classified into several subgroups based on the types of cells involved and the aggressiveness of the disease. Various treatments are used, including immunotherapy drugs that help the immune system fight cancer cells. This study (MK-4280-003) is intended for patients with classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), or indolent non-Hodgkin lymphoma (iNHL). The goal is to investigate the safety, optimal dosage, and efficacy of favezelimab in combination with pembrolizumab, both of which are immunomodulatory drugs. Adult patients who have one of these conditions and measurable tumors are eligible to participate.

18 years and older · Relapsed / refractory · Phase I/II

BGB-16673-101Recruiting

New treatment approach (drug: BGB-16673) as an adjunct to standard therapy with BTK inhibitors for various B-cell lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. A new mechanism of action (drug: BGB-16673) does not inhibit BTK but instead targets its destruction. The goal of the CaDAnCe-101 study is to investigate the optimal dosage, safety, and efficacy of the drug BGB-16673. Patients aged 18 and older with a variety of different NHLs are eligible to participate in the study. There must be no involvement of the central nervous system (CNS).

18 years and older · Relapsed / refractory · Phase I/II

ELM-2Recruiting

A new antibody (Odronextamab) for the treatment of B-cell non-Hodgkin lymphomas in patients who have already received prior treatment

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system that can occur in various subtypes. Standard treatment often consists of immunochemotherapy; however, the disease may remain active (refractory) or become active again (recurrence). Odronextamab is a new antibody that targets cancer cells while simultaneously stimulating the immune system (bispecific). It is already approved for treatment in certain situations. The ELM-2 study is investigating the efficacy and safety of this new antibody (odronextamab). The study is open to women and men aged 18 and older who have follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or another subtype of B-cell NHL, and whose disease is either refractory or has relapsed.

18 years and older · Relapsed / refractory · Phase II

MK-1026-003Recruiting

New Drug (Nemtabrutinib) for the Treatment of Various B-Cell Non-Hodgkin Lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a so-called Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. BTK inhibitors specifically target the metabolism of cancer cells and inhibit their growth. This study is investigating the optimal dosage, safety, and efficacy of a new BTK inhibitor called nemtabrutinib (MK-1026). Women and men aged 18 and older with certain types of NHL are eligible to participate in this study, including chronic lymphocytic leukemia (CLL/SLL), Richter syndrome, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström macroglobulinemia (WM).

18 years and older · Relapsed / refractory · Phase II